Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 1,721 Shares of Stock

Key Points

• Nektar Therapeutics insider Jonathan Zalevsky sold 1,721 shares at an average price of $33.52, totaling about $57,687.92, which represents an 8.97% decrease in his holdings.
• The company's stock traded up 10.3% on Monday, reaching $44.33, with a market cap of $843.16 million and a P/E ratio of -5.04.
• Nektar Therapeutics recently reported a quarterly earnings loss of ($2.95) per share, but surpassed revenue expectations with earnings of $11.18 million against a consensus estimate of $9.42 million.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 1,721 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $33.52, for a total transaction of $57,687.92. Following the sale, the insider directly owned 17,462 shares in the company, valued at $585,326.24. The trade was a 8.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, September 2nd, Jonathan Zalevsky sold 485 shares of Nektar Therapeutics stock. The shares were sold at an average price of $30.10, for a total transaction of $14,598.50.
• On Tuesday, August 19th, Jonathan Zalevsky sold 725 shares of Nektar Therapeutics stock. The shares were sold at an average price of $26.59, for a total value of $19,277.75.

Nektar Therapeutics Trading Up 10.3%

NASDAQ:NKTR traded up $4.15 during trading hours on Monday, reaching $44.33. 1,962,767 shares of the company traded hands, compared to its average volume of 839,362. The business's 50-day moving average price is $26.15 and its two-hundred day moving average price is $16.58. Nektar Therapeutics has a 1 year low of $6.45 and a 1 year high of $44.33. The stock has a market capitalization of $843.16 million, a P/E ratio of -5.04 and a beta of 1.05.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) earnings per share for the quarter, beating the consensus estimate of ($3.13) by $0.18. The firm had revenue of $11.18 million during the quarter, compared to the consensus estimate of $9.42 million. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%. As a group, equities analysts anticipate that Nektar Therapeutics will post -0.72 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on NKTR. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a report on Monday, May 12th. Wall Street Zen lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, May 14th. HC Wainwright upped their price objective on Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a research report on Tuesday, June 24th. B. Riley increased their target price on Nektar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Finally, BTIG Research boosted their price target on Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $88.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. US Asset Management LLC purchased a new position in Nektar Therapeutics in the fourth quarter worth about $31,000. Algert Global LLC purchased a new stake in shares of Nektar Therapeutics during the 1st quarter valued at about $33,000. US Bancorp DE lifted its stake in shares of Nektar Therapeutics by 257.8% in the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 36,085 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Nektar Therapeutics in the second quarter worth approximately $39,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Nektar Therapeutics during the first quarter valued at approximately $41,000. Institutional investors own 75.88% of the company's stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.